We hypothesized that targeting key points in the ischemic cascade with combined neuroglobin (Ngb) overexpression and c-jun N-terminal kinase (JNK) inhibition (SP600125) would offer greater neuroprotection than single treatment after in vitro hypoxia/ reoxygenation and in a randomized, blinded in vivo experimental stroke study using a clinically relevant rat strain. Male spontaneously hypertensive stroke-prone rats underwent transient middle cerebral artery occlusion (tMCAO) and were divided into the following groups: tMCAO; tMCAO þ control GFP-expressing canine adenovirus-2, CAVGFP; tMCAO þ Ngb-expressing CAV-2, CAVNgb; tMCAO þ SP600125; tMCAO þ CAVNgb þ SP600125; or sham procedure. Rats were assessed till day 14 for neurologic outcome before infarct determination. In vitro, combined lentivirus-mediated Ngb overexpression þ SP600125 significantly reduced oxidative stress and apoptosis compared with single treatment(s) after hypoxia/reoxygenation in B50 cells. In vivo, infarct volume was significantly reduced by CAVNgb, SP600125, and further by CAVNgb þ SP600125. The number of Ngb-positive cells in the peri-infarct cortex and striatum was significantly increased 14 days after tMCAO in animals receiving CAVNgb. Neurologic outcome, measured using a 32-point neurologic score, significantly improved with CAVNgb þ SP600125 compared with single treatments at 14 days after tMCAO. Combined Ngb overexpression with JNK inhibition reduced hypoxia/reoxygenation-induced oxidative stress and apoptosis in cultured neurons and reduced infarct and improved neurologic outcome more than single therapy after in vivo experimental stroke in hypertensive rats.
INTRODUCTION
Currently, reperfusion therapy with recombinant tissue plasminogen activator (rt-PA) is the cornerstone of treatment for acute ischemic stroke, yet therapy can only be delivered to a fraction of patients because of a narrow therapeutic window and risk of cerebral hemorrhage. 1 Extensive research has identified excitotoxicity, oxidative stress, inflammation, and cell death (necrosis and apoptosis) as key contributory pathways underlying lesion progression. 2 These diverse injury mechanisms may explain why pharmacotherapy clinical trials geared to manipulate single pathways have failed. A polytherapy approach targeting distinct pathways may be more effective and has shown promise in preclinical models, [3] [4] with the majority assessing the potential to extend the therapeutic window of rt-PA. Of these, 97% used young, healthy animals. 3 The revised STAIR 5 and other guidelines covering preclinical stroke studies 6 have highlighted the need to include comorbidities in preclinical stroke models to better model the clinical situation and improve assessment of new therapies. The most significant risk factors (hypertension, abdominal obesity, diet, physical inactivity, and current smoking) account for 80% of the global stroke risk, with self-reported history of hypertension being the strongest of these. 7 In this study we used spontaneously hypertensive stroke-prone rats (SHRSP) that display stroke comorbidities of hypertension, insulin resistance, and inflammation.
We chose to target two key pathways underlying stroke pathogenesis (oxidative stress and apoptosis) through neuroglobin (Ngb) upregulation in combination with c-jun N-terminal kinase (JNK) inhibition. Neuroglobin, a neuronal specific O 2 binding protein, is generally considered to mediate neuroprotection in preclinical stroke studies after overexpression; [8] [9] [10] [11] however, it is worth noting that, to date, neuroprotection has been shown in normal rodent strains but not in any strain exhibiting comorbidity. Administration of adeno-associated virus (AAV)-overexpressing Ngb significantly reduced lesion size and improved Bederson's 5-point neurologic score in young, normotensive rats after middle cerebral artery occlusion (MCAO). 10 Transgenic Ngb overexpression in mice reduced infarct volume after transient MCAO (tMCAO), 9, 11 but sensorimotor function remained unchanged. 11 Intravenous delivery of Ngb linked to a fusion protein 2 hours before tMCAO reduced infarct volume and neurologic deficit score in mice. 8 Adenovirus, AAV, and lentivirus have been used as viral vectors to overexpress neuroprotective genes that have resulted in reduced infarct volume and improved functional outcome in permanent and tMCAO models. 12 Here, canine adenovirus type 2 (CAV-2 vectors), a vector that preferentially transduces neurons and has been shown to transduce a greater volume of brain tissue through retrograde transport from the site of injection, [13] [14] was used.
To provide antiapoptotic protection, we targeted JNK, a downstream mediator of extrinsic and intrinsic apoptosis. A peptide inhibitor of JNK administered 6 hours after occlusion reduced lesion volume and improved functional outcome after tMCAO in mice 15 and reduced infarct volume when delivered 3 hours after permanent MCAO in mice. 16 After tMCAO in spontaneously hypertensive rats, however, no such neuroprotection was seen. 17 This was attributed, in part, to the predominance of AMPA (a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)-rather than NMDA (N-methyl-D-aspartate)-activated ischemic brain injury in the SHR. 17 One further reason may be the more severe ischemic insult induced by MCAO in SHR (and SHRSP), leading to a greater contribution of necrotic to apoptotic cell death. This could result in reduced efficacy of drugs targeting the JNK signaling pathway and highlights once again, the importance of including stroke associated comorbidities in preclinical studies. We used SP600125, an ATP-competitive inhibitor of JNK, shown previously to dose-dependently reduce infarct volume when administered intravenously o2 hours after tMCAO in mice. 18 The efficacy of these agents alone has not previously been determined in preclinical stroke models displaying clinically relevant comorbidities, and the novel combination of an antiapoptotic and an antioxidant represents a further advance.
MATERIALS AND METHODS

Virus Production
Because the expression of coxsackievirus and adenovirus receptor, the primary receptor for CAV-2, was negligible on B50 rat neuronal cells used for in vitro studies (Supplementary Figure S1A) , a Ngb-expressing lentivirus was generated with functional overexpression (mRNA and protein) confirmed ( Figures 1A and 1B ). Lentiviral vectors were produced by triple transient transfection of HEK293T cells with a packaging plasmid (pCMVD8.74), a plasmid encoding the envelope of vesicular stomatitis virus (Plasmid Factory, Bielefeld, Germany) and pHR-SIN-SFFV-Ngb, using polyethylenimine (Sigma-Aldrich, Poole, UK) as previously described. 19 For CAVNgb production, the Ngb complementary DNA was cloned from pET3a_Ngb into pTCAV-12VK and recombined with pTG5412 as previously described 20 and propagated in DKZeo cells. 21 
In Vitro Oxidative Stress Assays
Electron paramagnetic resonance (EPR) spectroscopy for reactive oxygen species (ROS) detection (e-scan R; Bruker BioSpin GmbH, Rheinstetten, Germany) used the spin probe 1-hydroxy-3-carboxy-2,2,5,5-tetramethylpyrrolidine (CPH; Noxygen, Elzach, Germany) as previously described. 22 Cells were incubated in situ with Krebs buffer and 1 mmol/L CPH in a total volume of 1 mL for 60 minutes at 37 1C for the last hour of the 24-hour reoxygenation period. Instrument settings were as follows: centre field of 3,392 G, modulation amplitude of 5.08 G, sweep time of 10.49 seconds, sweep width of 120 G, and 30 scans. In the presence of ROS, CPH is oxidized to the nitroxide CP radical and the triple-line spectrum is read giving the EPR amplitude in proportion to the amount of CP reflecting the interaction of ROS with CPH after 60 minutes, giving a rate of ROS production calculated in counts per minute. All readings were normalized for input protein using a BCA protein assay kit (Pierce, Northumberland, UK). A spectrophotometric assay (Tebu-Bio, Peterborough, UK) for malondialdehyde (MDA) was used to determine lipid peroxidation levels after hypoxia/reoxygenation (H/R) as per the manufacturer's instructions. The MDA and hydroxyalkenal determination protocol was used with 200 mL cell lysate (in PBS þ 5 mmol/L butylated hydroxytoluene). Reaction mixtures were incubated for 60 minutes at 45 1C before absorbance was measured at 586 nm in a spectrophotometer. All readings were normalized for input protein using a BCA protein assay kit (Pierce).
Apoptosis Assays
Apoptosis was measured with a cell death ELISA (Roche, Burgess Hill, UK) as per the manufacturer's instructions. Caspase-3 ICC was performed on 4% (w/v) paraformaldehyde-fixed cells. Briefly, cells were permeabilized in 0.1% (v/v) Triton/ PBS for 15 minutes before incubation with primary antibody (1:30 dilution; AB32351, Abcam) for 1 hour at RT. Secondary antibody (4 mg/mL, goat anti-rabbit Alexa Fluor 488, Invitrogen; A11008) was added for 1 hour at RT. Cells were mounted using Prolong Gold with DAPI (Invitrogen).
Animals
Animal experiments were performed in accordance with the Animals Scientific Procedures Act 1986 and approved by the Ethics Review Committee of the University of Glasgow. Male, SHRSP (n ¼ 65, 270 to 310 g) were housed separately under a 12:12 hour light/dark cycle with food and water ad libitum. Studies were randomized and masked, preventing bias in selection and data analysis in accordance with STAIR and other guidelines. [5] [6] For randomization, treatment groups were given a number (1 to 6) and animals randomly allocated to a treatment group by a colleague not involved in performing the study using R (www.r-project.org). Subject groups were: sham (n ¼ 6), control tMCAO (n ¼ 9), tMCAO þ CAVGFP (n ¼ 9), tMCAO þ CAVNgb (n ¼ 9), tMCAO þ SP600125 (n ¼ 9), and tMCAO þ CAVNgb þ SP600125 (n ¼ 8). The design of the in vivo intervention study is shown in Supplementary Figure S2 . Investigators and animal unit staff caring for the animals were masked to group allocation. Findings are reported in accordance with the ARRIVE guidelines. 23 
Virus and Drug Administration
Anesthetic was induced with 5% isoflurane in oxygen and animals intubated and ventilated throughout surgery (B2.5% isoflurane/oxygen). Body temperature was maintained at 37 ± 0.5 1C. Animals undergoing tMCAO had cranial burrhole surgery 5 days before tMCAO for virus administration or as a sham procedure. Interestingly, this prestroke surgery reduces subsequent stroke-related mortality. 24 Briefly, the head was secured in a stereotactic frame, a 1 mm cranial burrhole made, and a 24G needle connected to a Hamilton syringe used to pierce the dura and administer virus into the cortex. After a 2-minute rest period, 2.1 mL virus suspension was injected for 5 minutes, with a subsequent 2-minute rest period before slow needle retraction. A reporter gene-expressing lentivirus and CAV-2 were compared for transduction levels to determine which was the most efficient vector for this study. The CAV-2 vectors (3 Â 10 9 physical particles) were injected at coordinates: AP þ 1.2 mm, ML þ 3 mm, and DV À 2 mm relative to bregma; or two injections of 2 Â 10 7 vp lentivirus injected at coordinates: AP À 0.4 mm, ML þ 3 mm, and DV À 2 mm, and AP À 2.4 mm, ML þ 4 mm, and DV À 2 mm relative to bregma. For the intervention study, the site of CAV-2 injection (3 Â 10 9 physical particles) was AP À 0.7 mm, ML þ 3 mm, and DV À 2 mm relative to bregma. The burrhole was then sealed with dental cement (Wright Cottrell, Glasgow, UK). Animals randomized to SP600125 received an intravenous injection
15 minutes before and 3 hours after tMCAO as previously described in mice. 18 
Neurologic Assessments
Each animal was trained on the neurologic assessments before MCAO to ensure reproducibility at performing tasks. Animals were assessed on a single occasion 3 days before tMCAO to ascertain a baseline score. The 32-point neurologic score used was developed from a series of 10 tests that assess limb function, mobility, and general health; the lower the score, the greater the neurologic deficit. Animals were further assessed by the tapered beam walk test, quantifying the average number of footfalls as a percentage of the total number taken from 3 crossings of a 130-cm tapered beam. The animals were assessed at baseline 3 days before tMCAO and longitudinally on days 1, 2, 3, 7, 10, and 14 after MCAO. Where possible, behavioral measures were completed masked to surgery and treatment groups and were video recorded for assessment of footfalls and to allow for further validation of scores by a second masked observer.
Tail-Cuff Plethysmography
Conscious systolic blood pressure monitoring was performed by noninvasive computerized tail-cuff, based on the plethysmographic method. Rats were preheated to B39 1C for B20 minutes and restrained by wrapping in a surgical sheet, before a pneumatic pressure sensor was attached to the tail distal to a pneumatic pressure cuff, both under the control of a Programmed Electro-Sphygmomanometer (Harvard Apparatus, Kent, UK). Systolic blood pressure values from each animal were determined by averaging a minimum of six separate indirect pressure measurements.
Stroke Model
Animals were anesthetized as before and underwent tMCAO (45 minutes) by advancing a silicone-coated monofilament (Doccol, Sharon, MA, USA) through the internal carotid artery, blocking the origin of the MCA. 25 Animals were maintained under anesthesia during the ischemia and then anesthetic was withdrawn and the animals allowed to recover consciousness after removal of the filament. The duration of occlusion was determined to reflect a reproducible infarct volume and accompanying neurologic deficit but with an acceptably low mortality rate (60 minutes of MCAO resulted in 100% mortality in SHRSP within 2 to 3 days of experimental stroke, LM Work, unpublished observation).
Infarct Analysis
At 14 days after tMCAO, rats were killed by transcardiac perfusion fixation. Formalin-fixed, paraffin-embedded tissue sections (6 mm) were stained with hematoxylin and eosin. Infarct volume was assessed at seven coronal levels throughout the MCA territory. 26 Briefly, areas of tissue infarction were identified and the location transcribed onto scale line diagrams from the rat brain atlas. 27 Line diagrams were then scanned and infarct areas were measured by image analysis (ImageJ, NIH, Bethesda, MD, USA). The infarct volume (mm 3 ) for each brain was calculated by plotting the area (mm 2 ) of damage at each coronal level against the known anterior/ posterior stereotaxic coordinates from Bregma and calculating the area under the curve. Infarct measures were made masked to group allocation.
Immunohistochemistry for Virus Transduction
For determination of virus transduction efficiency and spread from the injection site, rats were killed by transcardiac perfusion fixation. Brains were then placed in a 30% (w/v) sucrose gradient and subsequently embedded in optimal cutting temperature (OCT). Frozen sections (40 mm) were permeabilized in 0.1% (v/v) Triton-X for 10 minutes and blocked for 1 hour at RT. Primary antibody or immunoglobulin G (IgG) control were diluted (1:500, GFP, Abcam, Ab6556; 1:500, NeuN, Millipore, Watford, UK, MAB377) and incubated on sections overnight at 4 1C. Fluorescent secondary antibody (4 mg/mL; goat anti-rabbit (GFP) or goat anti-mouse (NeuN) Alexa Fluor 488, Invitrogen, UK; A11008 or A11001, respectively) was incubated on the slides for 1 hour at RT before mounting with ProLong Gold with DAPI. Areas of virus transduction (GFP expression) were identified on brain sections and their location transcribed onto scale line diagrams at seven predetermined coronal levels. The area of GFP transduction of three sections at each coronal level were delineated onto the appropriate coronal line diagrams, and measured using image analysis (ImageJ, NIH).
To determine levels of Ngb overexpression after virus delivery before tMCAO, formalin-fixed, paraffin-embedded tissue sections (6 mm) were rehydrated, endogenous peroxidise quenched (30 minutes in 3% (v/v) H 2 O 2 in methanol), followed by citrate buffer antigen retrieval. Sections were blocked for 1 hour at RT and incubated overnight at 4 1C in primary antibody (1:200, Ngb, Sigma, Poole, UK; 1:200 NeuN, Abcam) or IgG control. Fluorescent secondary antibody (4 mg/mL; goat anti-mouse Alexa Fluor 546, Invitrogen, UK; A21424) was incubated on the slides for 1 hour at RT before mounting with ProLong Gold with DAPI. Images were taken on a Zeiss confocal imaging system LSM 510 (Carl Zeiss, UK) using settings DAPI (405) pinhole 61 mm and TRITC (546) pinhole 71 mm and objective C-apochromat 40x/1.2W at five matched locations across the cortex and striatum at two coronal levels (coordinates (mm): 5 sites at AP À 0.12 from Bregma À ML þ 3.5, DV À 1; ML þ 1, DV À 1; ML þ 2, DV À 4; ML þ 4, DV À 4; ML þ 3.5, DV À 6; and 5 sites at AP À 2.28 from Bregma À ML þ 4.5, DV À 1; ML þ 1, DV À 1; ML þ 4, DV À 4; ML þ 4.5, DV À 6; ML 1.5, DV À 4) to reflect the areas of high virus transduction and infarct. To quantify the extent of Ngb expression, Image Pro (Media Cybernetics, Basingstoke, UK) was used. The area for quantification of Ngb cell count in peri-infarct tissue was selected using the Area of Interest Macro and pixel values were transformed to optical density units. The number of cells positive for Ngb was then determined as a percentage of the total number of DAPI-stained nuclei within each given field. Image acquisition and subsequent quantifications were performed masked to group allocation.
Statistics
Data are presented as mean ± s.e.m. In vitro experiments were performed in triplicate on X3 independent occasions and analyzed by unpaired Student's t-test. In vivo groups were compared using repeated measures analysis of variance (ANOVA). Survival rates were compared using Fisher's exact test. Bonferroni's or Tukey's post hoc test was used for multiple comparisons. 
RESULTS
Neuroglobin Overexpression Combined with c-Jun N-Terminal
Kinase Inhibition Protects Against Hypoxia/Reoxygenation In Vitro B50 neuronal cells subjected to 9 hours of hypoxia and 24 hours of reoxygenation produced significant increases in ROS generation (Figure 2A ), MDA ( Figure 2B ), DNA fragmentation ( Figure 2C ), and caspase-3 nuclear translocation ( Figure 2D ). Lenti-Ngb pretreatment significantly reduced ROS generation versus controls (Figure 2A ). SP600125 treatment alone did not significantly reduce ROS levels but potentiated the lenti-Ngb-mediated reduction (Figure 2A) . The MDA levels appeared maximally reduced in cells pretreated with lenti-Ngb or SP600125. Consequently, no further benefit of combined therapy was observed ( Figure 2B ). Lenti-Ngb or SP600125 pretreatment significantly reduced levels of apoptosis, with a further significant reduction from that seen with lenti-Ngb after combined intervention ( Figure 2C ). In all assays, in cells pretreated with the lenti-Ngb or SP600125 and the appropriate control treatments (DMSO or lenti-GFP), the same effect as the single active agent (either lenti-Ngb or SP600125) was found, showing no confounding effect attributable to either vehicle or virus. Caspase-3 nuclear translocation was assessed qualitatively by ICC ( Figure 2D ). Lenti-Ngb or SP600125 pretreatment reduced the extent of nuclear translocation of caspase-3 with combined treatment returning the cellular distribution pattern of caspase-3 to that of normoxic cells ( Figure 2D ).
Canine Adenovirus Type 2 Vectors More Efficiently Transduce the Adult Rat Cortex Than Lentivirus
Different levels and distribution of reporter gene, GFP, expression were found for the reporter gene-expressing lentivirus and CAV-2 ( Figures 3A and 3B) . One week after a single cortical injection of CAV-2, the rostro-caudal spread from the injection site was in excess of 7 mm with spread through the cortical parenchyma. In contrast, after double cortical injection of lentivirus, the spread was minimal (o 2.5 mm) from the site(s) of injection ( Figures 3A and 3B) . Determination of the tissue volume expressing the reporter gene, GFP, showed that seen with the CAV-2 vector was significantly greater than that resulting from a double cortical injection of lentivirus (156±11.1* versus 20±3.8 mm 3 ; *Po0.0002 versus lentivirus; Figure 3 . Comparative transduction levels from canine adenovirus type 2 (CAV-2) and lentivirus in adult rat brain. (A) Rostro-caudal gene transduction (grey) after single injection of 3 Â 10 9 virus particle (vp) CAVGFP (n ¼ 4; left) and double injection of 2 Â 10 7 vp lenti-GFP (n ¼ 4; right) determined from the median animal in each virus group. Black dots represent cortical injection sites. The staining pattern of green fluorescent protein (GFP) expression was transcribed onto stereotaxic atlas plates. 27 (B) Representative cortical images of GFP epifluorescence from lentivirus or CAV-2 transduction 7 days after stereotactic injection; scale bar, 100 mm (top) and 20 mm (bottom). Images taken from the primary somatosensory cortex (S1FL) at coronal level Bregma À 0.12 mm (indicated with an X on atlas plate image). (C) Volume of tissue transduced by each viral vector quantified from area under the curve analysis across seven coronal levels. Data presented as mean±s.e.m.; *Po0.0002 versus lentivirus using Student's unpaired t-test. Figure 3C ). Therefore, a Ngb-expressing CAV-2 virus was generated for in vivo studies and functional Ngb overexpression (mRNA and protein) confirmed in vitro ( Figures 1C and 1D , respectively). Expression of CAR mRNA, the primary receptor for CAV-2 virus, in the brain of SHRSP was confirmed (Supplementary Figure S1B ).
Neuroglobin Overexpression Combined with c-Jun N-Terminal Kinase Inhibition Protects In Vivo Against Cerebral Ischemia/ Reperfusion
Virus-mediated overexpression of neuroglobin. Neuroglobin expression was determined 14 days after tMCAO across all groups ( Figure 4A ), 19 days after the CAV-2 vector was administered. In control tMCAO animals, there was a small, nonsignificant increase in the number of cells expressing Ngb in the peri-infarct cortical and striatal regions (9.9±1.3%) compared with sham animals (3.1 ± 0.5%; Figure 4B ). Similarly, no significant change in the number of cells positive for Ngb expression was seen in animals randomly allocated to receive SP600125 (5.8±1.1%; Figures 4A and 4B) . The endogenous expression of Ngb in these groups was largely restricted to the peri-infarct region ( Figure 4A ). In animals receiving CAVNgb alone (25 ± 3.1%) or in combination with SP600125 (24.6 ± 2.2%), there was a marked and significant increase in the number of cells positive for Ngb expression within the peri-infarct cortex and striatum 19 days after virus administration ( Figure 4A ) compared with sham-, control tMCAO-, or SP600125-treated animals ( Figure 4B ). The increased Ngb expression in CAVNgb-treated groups was evident in both cortical and striatal regions around the infarct ( Figure 4A) . The rostro-caudal spread in enhanced Ngb expression after tMCAO appeared consistent with that seen for CAVGFP ( Figure 3) , with increased expression evident over a rostro-caudal distance of B7 mm from the site of injection. Ngb expression was primarily colocalized with NeuN-positive cells indicating a neuronal expression. Note that not all NeuN-positive cells appear positive for Ngb ( Figure 4C ).
Survival and systolic blood pressure. No intervention affected systolic blood pressure (SBP) at 7 or 14 days after tMCAO (Table 1 ). Furthermore, there was no significant difference in the starting/ final SBP values between groups. The associated weight loss after tMCAO was similar between groups ( Table 1 ). Survival over the duration of the study was 100% in the sham (6/6) and tMCAO with combined intervention (8/8) groups only. Although mortality occurred in the other groups, survival rates were not significantly different between groups: tMCAO, 9/13; tMCAO þ CAVNgb, 9/10; tMCAO þ SP600125, 9/13; and tMCAO þ CAVGFP, 9/11 ( Figure 5A ).
Infarct volume. Infarct volumes were comparable in untreated tMCAO control (324 ± 16.4 mm 3 , n ¼ 9) and tMCAO þ CAVGFP (314±22.2 mm 3 , n ¼ 9) rats ( Figure 5B ). Treatment with SP600125 and CAVNgb (n ¼ 9 per group) significantly reduced infarct volume by 33.8% (215 ± 34.2 mm 3 *) and 38.6% (199 ± 14.4 mm 3 *), respectively compared with control tMCAO (*Po0.01 versus tMCAO). Importantly, combined intervention (n ¼ 8) produced a greater reduction in infarct volume than single treatments (57%; 137±20.7 mm 3 , * w Po0.01 versus *tMCAO or w SP600125 and CAVNgb). The rostro-caudal extent of infarction in each group is shown in Figure 5C . Morphologic analysis showed that in animals receiving CAVNgb, SP600125, or CAVNgb þ SP600125, the extent of infarct in the primary motor cortex and striatum was reduced versus control tMCAO or CAVGFP ( Figure 5D ). However, there was a region in the primary somatosensory forelimb and hindlimb cortex that was consistently infarcted irrespective of intervention ( Figure 5D , middle panel).
Neurologic deficit. All tMCAO groups exhibited a significant reduction in neurologic score from baseline at 24 hours after tMCAO ( Figure 6A ). No significant difference in neurologic score was observed between groups over days 1 to 3. At day 7, a significant improvement in neurologic recovery was observed with combined therapy compared with control tMCAO. However, at day 10, there was a significant improvement with single treatment groups compared with control tMCAO, but no further improvement with combination therapy. By day 14, single treatments significantly improved neurologic score, with combined therapy producing a further significant improvement compared with single treatments ( Figure 6A ). All tMCAO groups exhibited a significant increase in percentage footfalls 24 hours after tMCAO on the tapered beam walk test ( Figure 6B ). By day 14, a significant improvement in total footfalls was evident in all treatment groups versus the control group. However, no additional improvement with combined therapy was observed ( Figure 6B ).
DISCUSSION
We describe, for the first time, an improved beneficial effect (both reduced infarct volume and improved neurologic recovery determined longitudinally) through combined antiapoptotic and antioxidant intervention in a clinically relevant stroke model displaying stroke-associated comorbidities. Combined intervention mediated greater neuroprotection than either therapy alone, both in vitro using a model of H/R and in vivo after tMCAO. Furthermore, this study introduces neurotrophic CAV-2 vector as a platform that will allow better understanding of stroke pathophysiology through high levels of brain transduction. Together, this supports the potential for combined intervention strategies; in this case, targeting excessive oxidative stress and apoptosis after cerebral ischemia.
In vitro studies showed that Ngb overexpression combined with JNK inhibition mediated greater neuroprotection and less oxidative stress and apoptosis after H/R injury compared with individual treatments. Although each single treatment has been studied previously in neuronal cells in vitro, combination therapy has not. Immortalized HN33 hippocampal neurones transfected to overexpress Ngb exhibited improved cell viability, measured by MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay, after 8 or 24 hours of anoxia. 28 Additional mechanistic studies determined that there was no increase in oxygen consumption in Ngb-overexpressing cells compared with controls, and an involvement of nitric oxide scavenging was further ruled out through the failure of Ngb to protect against sodium nitroprusside-induced toxicity. 28 It has since been shown that Ngb elicits protection from H/R insult in vitro through multiple mechanisms including improving mitochondrial function, maintenance of intracellular ATP levels, inhibition of calcium influx, binding to cytochrome c, and reduced caspase 3/7 and 9 activity in human neuroblastoma cells overexpressing Ngb. [29] [30] [31] In this study, vector-mediated Ngb overexpression resulted in reduced ROS generation ( Figure 2 ). Although Ngb was initially believed to act purely as an antioxidant, studies 29, 31 including this study suggest antiapoptotic effects through an interaction with cytochrome c, reduced caspase 3/7 or 9 activity/nuclear localization, and DNA fragmentation (reviewed in Brittain 32 ). It is impossible to distinguish unequivocally between apoptotic and oxidative stress pathways as they are inextricably linked with extensive crosstalk between them. However, Ngb directly activates the PI3K/AKT/mTOR (phosphatidylinositide 3-kinase/ AKT/ mammalian target of rapamycin) pathway of cell survival. 33 Furthermore, JNK may be involved in prooxidant pathways because the N-terminal Von Hippel-Lindau recognition site of hypoxia inducible factor-1a contains a JNK-binding domain. 34 Notably, translation to an in vivo stroke model confirmed that combined Ngb upregulation and JNK inhibition was better than single treatment using infarct size and neurologic deficit as outcome measures (Figures 4-6 ). The greatest reduction in infarct size, detected in the combination treatment group, was accompanied by an improved neurologic score and reduction in footfalls at day 14. The tapered beam walk test failed to show any additional improvement with combined treatment, which likely reflects the conserved region of infarct within the primary somatosensory forelimb/hindlimb cortex in all groups ( Figure 5D ). There was a trend toward an increase in endogenous Ngb levels at 14 days after tMCAO in the SHRSP, although this was not significantly enhanced compared with sham ( Figure 4 ). We cannot exclude the possibility that peak Ngb levels occurred earlier and returned toward basal levels 2 weeks after cerebral ischemia. Endogenous upregulation of Ngb in cells in the periinfarct region agrees with other preclinical 28 and clinical stroke studies 35 where increased Ngb levels were reported. Importantly, virus-mediated overexpression of Ngb was sustained to 14 days after tMCAO (19 days after administration) in animals randomized to receive CAVNgb or the combined treatment. Interestingly, in SP600125-treated animals, which had a similar infarct volume to the CAVNgb single intervention group, there was no difference in the number of Ngb-positive cells compared with sham. This may reflect that with the smaller infarct resulting from SP600125 treatment, the stimulus for endogenous Ngb upregulation after tMCAO was reduced. Interestingly, in the intervention study, increased Ngb expression was detected in the striatum and cortex after virus delivery and tMCAO. Striatal gene expression was not evident from the CAVGFP administration in naive rats (Figure 3 ). Although we cannot distinguish between endogenous or virusmediated upregulation in Ngb expression within the striatum, we can postulate that after tMCAO transduction profiles may differ or that there is an active transport process occurring similar to what has previously been described with CAV-2 vectors. 36 Previous studies determining the neuroprotective effect of Ngb in vivo showed Ngb-overexpressing transgenic mice had lower levels of lipid peroxidation measured by MDA assay in the ipsilateral hemisphere after tMCAO. 11 In addition, reduced numbers of TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling)-positive cells and increased numbers of neurones with a normal morphology (from cresyl violet histology) were seen after delivery of Ngb linked to a fusion protein before tMCAO in C57BL/6J mice. 8 This shows that in spite of the multifaceted mechanism of action of Ngb (antioxidant and antiapoptotic), further protection can be afforded through combined JNK inhibition. All previous experimental stroke reports of neuroprotection afforded by Ngb have been determined in normal mice or rats or using transgenic overexpression. [8] [9] [10] [11] In using SHRSP, which exhibit a number of stroke-related comorbidities, we have addressed STAIR guidelines 5 as hypertension was reported as the strongest risk factor for stroke in a global case study. 7 Furthermore, all analyses were performed under masked conditions with animals randomly assigned to experimental groups and blood pressure monitoring throughout, in accordance with the preclinical stroke study guidelines. 6 Of the 142 publications describing combined therapy for stroke, only 3% have used hypertensive rats. 3 The majority of these determined the potential for adjuvant therapy to extend the therapeutic window for rt-PA. 4 Only one combination treatment study (antioxidant tempol and/or cannabinoid/NMDA antagonist dexanabinol after permanent MCAO) used hypertensive rats and this failed to identify any additional benefit of combined treatment, attributing this to a ceiling neuroprotection achieved by either single treatment. 37 We designed our study to limit this possibility. The dose of SP600125 used (1 mg/kg) was selected based on previous studies in mice showing a significant, but submaximal (seen at 3 mg/kg), reduction in infarct volume after tMCAO 18 in an attempt to avoid a similar ceiling effect. A recovery period of 14 days was set to ensure capture of final infarct size (shown previously to continue to evolve 48 to 72 hours after tMCAO in rats 38 ) and allow serial assessment of neurologic outcome measures.
The utility of CAV-2 vectors for neurodegenerative diseases has previously been shown in dopamine-deficient mice where CAV-2transduced neurons expressed tyrosine hydroxylase for 41 year from delivery. 39 More recently, in a lysosomal storage disorder, neonatal delivery led to persistant transgene expression and normalization of the functional deficit for up to 20 weeks. 40 A single cortical CAV-2 injection efficiently transduced neurons and resulted in an eightfold greater transduction volume and covered a greater rostro-caudal distance than lentivirus in the present study. In the first study using CAV-2 in a cerebral ischemia model, increased levels of Ngb transduction remained in neurons of periinfarct cortical and striatal regions 2 weeks after tMCAO and 19 days after CAV-2 delivery, showing sustained and selective transgene expression. Gene-and cell based-therapies are now being clinically tested for a wide range of diverse disease pathologies. Although the success of the CAV-2 vector to directly deliver Ngb to the brain parenchyma overcomes limitations relating to the ability of pharmacological antioxidants to reach the brain by failure to cross the blood-brain barrier, translation of novel gene delivery vectors, such as CAV-2, will require further extensive preclinical research. A more feasible clinical prospect may be through pharmacological upregulation of Ngb to similar levels achieved with CAV-2 vectors. A recent study described the use of the prolyl hydroxylase inhibitor (PHI) deferoxamine and the short-chain fatty acids cinnamic and valproic acids to pharmacologically increase Ngb expression in HN33 cells in vitro. 41 However, whether such an effect on Ngb expression is also evident in vivo has yet to be described. In addition, these agents are likely to affect a number of pathways in addition to merely upregulating Ngb-the PHIs, for example, enhance levels of hypoxia inducible factor-1a and -2a, resulting in neuroprotection through a plethora of target pathways. 42 In conclusion, the combination of antiapoptotic JNK inhibition and antioxidant Ngb upregulation shows a significant neuroprotective potential when administered before tMCAO. This study shows that targeting these pathways in combination improves efficacy compared with a single target using an animal model exhibiting stroke-associated comorbidities. Further use of such a combined approach targeting excessive oxidative stress and apoptosis may be applicable in disease settings where these pathways are implicated, such as neurodegenerative disorders (Alzheimer's disease, Parkinson's disease), traumatic brain injury, or hypoxic insult (such as hypoxic-ischemic neonatal encephalopathy, a problem in perinatal medicine). The next step in stroke translation will be to assess if neuroprotection and improved outcome can be achieved when treatment is delivered in the acute poststroke period and if it can act additively or synergistically with thrombolysis. However, although many single and combination therapeutic approaches have proven successful in preclinical models, this has not led to successful translation in stroke patients, and thrombolysis within a tight time frame of the onset of acute cerebral ischemia remains the primary intervention at this time.
